Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 6;12:681053. doi: 10.3389/fgene.2021.681053

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Sharma, Mir and Galande.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Chemotherapeutic interventions targeting the components of the Wnt signaling pathway. Drugs leading to the activation of the Wnt response inhibitors and repression of the Wnt response activators are being used as therapeutic agents for cancer therapy (or are under clinical trials). Wnt1 monoclonal antibody (MAb), Vantictumab and Ipafricept target the upstream regulators of the Wnt pathway. WNT974 blocks PORCN which prevents processing of Wnt ligands. IWR-1 and XAV939 act by activating AXIN, thereby stabilizing the Wnt destruction complex. PRI-724 acts by inhibiting the interaction of β-catenin with CBP/p300. PKF115-584, CGPO49090, PKF222-815, iCRT3, iCRT5, and iCRT14 act by inhibiting interaction of β-catenin with TCF/LEF.